CNC Share Price | Centene Corp. Stock Analysis & Recommendation

Q: How big is Centene Corp.?

As of Jun 18, Centene Corp. has a market capitalization of 28,268.27 million, categorizing it as a Large Cap company.As of Jun 24, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is 3,450.00 million.As of Dec 24, the reporting period shows Shareholder's Funds at 26,410.00 million and Total Assets at 83,584.00 million.

Q: What does Centene Corp. do?

Overview:Centene Corporation is a healthcare company that provides a portfolio of services to government-sponsored healthcare programs, focusing on under-insured and uninsured individuals, operating in the Healthcare Services industry with a large-cap market capitalization.Financial Snapshot:Net Profit: 1,314 Million (Quarterly Results - Mar 2025)Market cap: USD 28,268.27 Million (Large Cap)Key Metrics:P/E: 8.00Dividend Yield: 0.00%Debt Equity: 0.04Return on Equity: 12.43%Price to Book: 1.01Contact Details:Address: 7700 Forsyth Blvd, ST. LOUIS MO: 63105-1807Tel: 1 314 7254477Fax: 1 302 6555049Website: https://www.centene.com/

Q: Who are in the management team of Centene Corp.?

As of March 2022, the management team of Centene Corp. includes Mr. Michael Neidorff, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features several independent directors: Mr. Orlando Ayala, Ms. Jessica Blume, Ms. H. James Dallas, Mr. Robert Ditmore, and Mr. Frederick Eppinger, with Mr. Ditmore also holding the position of Presiding Independent Director.

Q: Is Centene Corp. overvalued or undervalued?

As of 25 July 2025, the valuation grade for Centene Corp. has moved from very attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued, given its P/E ratio of 8, which is significantly lower than its peer Humana, Inc., which has a P/E of 37.35, and the industry average is not provided. Additionally, Centene's EV to EBITDA stands at 23.58, while its PEG ratio is a favorable 0.53, suggesting potential growth relative to its price.In comparison to its peers, Centene Corp. is positioned as fair, while Humana, Inc. is deemed very expensive, highlighting a stark contrast in valuation metrics. The stock has underperformed against the S&P 500 across multiple time frames, with a year-to-date return of -46.90% compared to the index's 12.22%, reinforcing the notion that Centene may be overvalued in the current market context.

Q: Is Centene Corp. technically bullish or bearish?

As of 9 September 2025, the technical trend for Centene Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, with key indicators such as the MACD showing a mildly bullish signal on the weekly timeframe but bearish on the monthly. The RSI is bullish on the monthly but shows no signal on the weekly. Moving averages are mildly bearish on the daily, and both the KST and OBV indicate bearish trends on the weekly and monthly. In terms of performance, Centene's returns have significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -46.90% compared to the S&P 500's 12.22%, and a one-year return of -57.85% versus 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

13.29 M

Shareholding (Dec 2025)

FII

26.41%

Held by 441 FIIs

DII

27.07%

Held by 100 DIIs

Promoter

1.91%

How big is Centene Corp.?

22-Jun-2025

As of Jun 18, Centene Corp. has a market capitalization of $28.27 billion. As of Dec 24, the company reported shareholder's funds of $26.41 billion and total assets of $83.58 billion.

View full answer

What does Centene Corp. do?

22-Jun-2025

Centene Corporation is a healthcare company that offers services primarily to government-sponsored programs for under-insured and uninsured individuals, with a market cap of approximately $28.27 billion. As of March 2025, it reported a net profit of $1.31 billion and key metrics include a P/E ratio of 8.00 and a return on equity of 12.43%.

View full answer

Who are in the management team of Centene Corp.?

22-Jun-2025

As of March 2022, Centene Corp.'s management team is led by Mr. Michael Neidorff as Chairman, President, and CEO, with independent directors including Mr. Orlando Ayala, Ms. Jessica Blume, Mr. H. James Dallas, Mr. Robert Ditmore (also Presiding Independent Director), and Mr. Frederick Eppinger.

View full answer

Is Centene Corp. overvalued or undervalued?

20-Sep-2025

As of July 25, 2025, Centene Corp. is considered fairly valued but appears overvalued with a P/E ratio of 8 compared to Humana's 37.35, and has underperformed the S&P 500 with a year-to-date return of -46.90%.

View full answer

Is Centene Corp. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Centene Corp. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -46.90% versus the S&P's 12.22%.

View full answer

Compare Centene Corp. with Similar Stocks

Humana, Inc.The Cigna Group Elevance Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at USD 1,730 MM
ROCE(HY) Lowest at 7.5%
OPERATING PROFIT(Q) Lowest at USD -402 MM

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Healthcare Services

Market cap

USD 17,692 Million (Mid Cap)

P/E

27.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.14

Return on Equity

3.30%

Price to Book

0.89

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-1,100 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-12.29%

6 Months

6.93%

1 Year

-42.34%

2 Years

-55.34%

3 Years

-45.0%

4 Years

-60.79%

5 Years

-45.89%

Centene Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.88%

EBIT Growth (5y)

49.71%

EBIT to Interest (avg)

1.53

Debt to EBITDA (avg)

13.55

Net Debt to Equity (avg)

0.66

Sales to Capital Employed (avg)

3.88

Tax Ratio

23.84%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

3.93%

ROE (avg)

12.24%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.89

EV to EBIT

EV to EBITDA

11.70

EV to Capital Employed

0.87

EV to Sales

0.08

PEG Ratio

Dividend Yield

ROCE (Latest)

ROE (Latest)

3.30%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 168 Schemes (44.61%)

Foreign Institutions

Held by 441 Foreign Institutions (26.41%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 83.41% vs -2,460.62% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "329.00",
          "val2": "317.00",
          "chgp": "3.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "168.00",
          "val2": "170.00",
          "chgp": "-1.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-528.00",
          "val2": "-6,752.00",
          "chgp": "92.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,100.00",
          "val2": "-6,632.00",
          "chgp": "83.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-24.50%",
          "val2": "-4.10%",
          "chgp": "-2.04%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -302.70% vs 22.05% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,275.00",
          "val2": "1,241.00",
          "chgp": "2.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "678.00",
          "val2": "702.00",
          "chgp": "-3.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-7,338.00",
          "val2": "-108.00",
          "chgp": "-6,694.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6,677.00",
          "val2": "3,294.00",
          "chgp": "-302.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1.50%",
          "val2": "20.10%",
          "chgp": "-2.16%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

329.00

317.00

3.79%

Interest

168.00

170.00

-1.18%

Exceptional Items

-528.00

-6,752.00

92.18%

Consolidate Net Profit

-1,100.00

-6,632.00

83.41%

Operating Profit Margin (Excl OI)

-24.50%

-4.10%

-2.04%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 83.41% vs -2,460.62% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

1,275.00

1,241.00

2.74%

Interest

678.00

702.00

-3.42%

Exceptional Items

-7,338.00

-108.00

-6,694.44%

Consolidate Net Profit

-6,677.00

3,294.00

-302.70%

Operating Profit Margin (Excl OI)

-1.50%

20.10%

-2.16%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -302.70% vs 22.05% in Dec 2024

All Annual Results

Company CV

About Centene Corp.

Centene Corp.

Healthcare Services

Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company's Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children's Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace. Its Specialty Services segment consists of its specialty companies offering a range of healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations, as well as to its own subsidiaries.

Company Coordinates

Company Details

7700 Forsyth Blvd , ST. LOUIS MO : 63105-1807

Tel: 1 314 7254477

https://www.centene.com/

Registrar Details